Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Blood (2015) 126 (23): 2580.

https://doi.org/10.1182/blood.V126.23.2580.2580

Published: 2015

Journal Articles

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Rongqing Pan, MS, Vivian Ruvolo, MS, Hong Mu, MD PhD, Zhuanzhen Zheng, PhD, Joel Leverson, PhD, Kensuke Kojima, PhD, Marina Konopleva, MD PhD, Gwen Nichols, MD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 673.

https://doi.org/10.1182/blood.V126.23.673.673

Published: 2015

Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Blood (2014) 124 (21): 116.

https://doi.org/10.1182/blood.V124.21.116.116

Published: 2014

Journal Articles

Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)

Rongqing Pan, MS, Kensuke Kojima, MD PhD, Zhuanzhen Zheng, MD PhD, Vivian R Ruvolo, MA, Gwen Nichols, MD, Joel D. Leverson, PhD, Markus Dangl, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 2162.

https://doi.org/10.1182/blood.V124.21.2162.2162

Published: 2014

Journal Articles

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Karen Yee, MD, Giovanni Martinelli, MD, Sarit Assouline, MD, Margaret Kasner, MD, Norbert Vey, MD PhD, Kevin R. Kelly, MD, PhD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Michael Dennis, FRCP, FRCPath, Karen Seiter, MD, Steven Blotner, PhD, Lori Jukofsky, Steven Middleton, PhD, Jianguo Zhi, PhD, Gong Chen, PhD, Hua Zhong, PhD, Gwen Nichols, MD

Blood (2013) 122 (21): 498.

https://doi.org/10.1182/blood.V122.21.498.498

Published: 2013

Journal Articles

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Blood (2012) 120 (21): 675.

https://doi.org/10.1182/blood.V120.21.675.675

Published: 2012

Journal Articles

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Vivian Ruvolo, Anas Younes, MD, Wei Wei, Marina Konopleva, MD, PhD, Seshagiri Duvvuri, Xuelin Huang, PhD, Lin Wu, PhD, Lori Jukofsky, Lyubomir Vassilev, PhD, Jianguo Zhi, PhD, David Geho, MD, Gwen Nichols, MD

Blood (2011) 118 (21): 1545.

https://doi.org/10.1182/blood.V118.21.1545.1545

Published: 2011

Journal Articles

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Swaminathan Padmanabhan, MD, Roger Strair, MD, Mark Kirschbaum, MD, Peter Maslak, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Susan O'Brien, Felipe Samaniego, Gautam Borthakur, MD, Marina Konopleva, MD, PhD, Lyubomir Vassilev, PhD, Gwen Nichols, MD

Blood (2010) 116 (21): 657.

https://doi.org/10.1182/blood.V116.21.657.657

Published: 2010

Journal Articles

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

David H. Gordon, MD, Gwen Nichols, MD, Ali Ben-Jacob, MD, Hung Lam, PhD, Tom Lillie, MD, PhD, Carole Miller, MD

Blood (2006) 108 (11): 1304.

https://doi.org/10.1182/blood.V108.11.1304.1304

Published: 2006

Journal Articles

The Role of T Cell Costimulation by CD80 in the Immune Response to Human Waldenstrom’s Macroglobulinemia.

Wei Cai, PhD, Zhuoru Liu, Ph.D., Eckhardt Podack, M.D., Ph.D., Paul Harris, Ph.D., Gwen Nichols, M.D.

Blood (2006) 108 (11): 4743.

https://doi.org/10.1182/blood.V108.11.4743.4743

Published: 2006

Journal Articles

Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia

Steven P. Treon, Morie A. Gertz, Meletios Dimopoulos, Athanasios Anagnostopoulos, Joan Blade, Andrew R. Branagan, Ramon Garcia-Sanz, Stephen Johnson, Eva Kimby, Veronique LeBlond, Jean-Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin J. Stone

Blood (2006) 107 (9): 3442–3446.

https://doi.org/10.1182/blood-2005-02-0833

Published: 2006

Journal Articles

Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results.

John P. Leonard, MD, Richard R. Furman, MD, Ying-Kuen K. Cheung, Ph.D, Eric J. Feldman, MD, Hearn J. Cho, M.D, PhD, Julie M. Vose, MD, Gwen Nichols, MD, Patricia W. Glynn, Maureen A. Joyce, Jamie Ketas, Jia Ruan, MD, PhD, John Carew, MD, Ruben Niesvizky, MD, Ann LaCasce, MD, Amy Chadburn, MD, Ethel Cesarman, MD, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 491.

https://doi.org/10.1182/blood.V106.11.491.491

Published: 2005

NARROW

Europeanpediatric Acute Leukemia (EuPAL) Registry

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

The Role of T Cell Costimulation by CD80 in the Immune Response to Human Waldenstrom’s Macroglobulinemia.

Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia

Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only